Multiple molecular disease diagnoses were made in nearly 5 percent of individuals where exome sequencing was informative.
Sophia's platform will be used to analyze data from Devyser's hereditary breast cancer and cystic fibrosis testing kits.
The company's recently launched nucleic acid isolation and purification kit is just one of several new products the company hopes bring to the market over the next few years.
Ambry's new lab provides a streamlined, automated workflow that has allowed the company to triple its daily testing volume since it opened more than four months ago.
The companies will combine MolecularMD's specialty diagnostic assays with Definiens' quantitative tissue read-outs to provide customized diagnostic solutions in oncology.
When molecular testing did affect the surgical plan, it often led to overtreatment, according to the Johns Hopkins University School of Medicine team.
OpGen will add a commercial data visualization portal to its CLIA testing service and launch an integrated product and services offering this year.
Researchers outlined nine regulatory research-related challenges to validating, advancing, and improving next-generation sequencing-based diagnostic tests.
RNA sequencing uncovered differentially expressed genes in individuals with Lyme disease at diagnosis, immediately after antibiotic treatment, and six months later.
The companies plan to combine ACD's RNAscope in situ hybridization assays with Leica's clinical advanced staining instruments to develop tissue-based diagnostics.
In PLOS this week: nasal microbial communities in asthma patients; sequencing-based way to detect, track schistosomiasis; and more.
The New York Times speaks with Vanderbilt's John Anthony Capra about Neanderthal genes in modern humans.
A draft guidance from the FDA suggests the agency wants to more tightly control gene-edited animals, according to Technology Review.
Researchers were among this weekend's protesters bemoaning the new US administration, Vox reports.